Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/9190
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMotbey, CP-
dc.contributor.authorClemens, KJ-
dc.contributor.authorApetz, N-
dc.contributor.authorWinstock, AR-
dc.contributor.authorRamsey, J-
dc.contributor.authorLi, KM-
dc.contributor.authorWyatt, NA-
dc.contributor.authorCallaghan, PD-
dc.contributor.authorBowen, MT-
dc.contributor.authorCornish, JL-
dc.contributor.authorMcGregor, IS-
dc.date.accessioned2020-03-23T03:31:27Z-
dc.date.available2020-03-23T03:31:27Z-
dc.date.issued2013-06-05-
dc.identifier.citationMotbey, C. P., Clemens, K. J., Apetz, N., Winstock, A. R., Ramsey, J., Li, K. M., Wyatt, N., Callaghan, P. D., Bowen, M. T., Cornish, J. L., & McGregor, I. S. (2013). High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. Journal of psychopharmacology, 27(9), 823-836. doi:10.1177/0269881113490325en_AU
dc.identifier.govdoc8824-
dc.identifier.issn0269-8811-
dc.identifier.urihttp://dx.doi.org/10.1177/0269881113490325en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/9190-
dc.description.abstractMephedrone (MMC) is a relatively new recreational drug that has rapidly increased in popularity in recent years. This study explored the characteristics of intravenous MMC self-administration in the rat, with methamphetamine (METH) used as a comparator drug. Male Sprague-Dawley rats were trained to nose poke for intravenous MMC or METH in daily 2 h sessions over a 10 d acquisition period. Dose-response functions were then established under fixed- and progressive-ratio (FR and PR) schedules over three subsequent weeks of testing. Brains were analyzed ex vivo for striatal serotonin (5-HT) and dopamine (DA) levels and metabolites, while autoradiography assessed changes in the regional density of 5-HT and serotonin transporter (SERT) and DA transporter (DAT) and induction of the inflammation marker translocator protein (TSPO). Results showed that MMC was readily and vigorously self-administered via the intravenous route. Under a FR1 schedule, peak responding for MMC was obtained at 0.1 mg/kg/infusion, versus 0.01 mg/kg/infusion for METH. Break points under a PR schedule peaked at 1 mg/kg/infusion MMC versus 0.3 mg/kg/infusion for METH. Final intakes of MMC were 31.3 mg/kg/d compared to 4 mg/kg/d for METH. Rats self-administering MMC, but not METH, gained weight at a slower rate than control rats. METH, but not MMC, self-administration elevated TSPO receptor density in the nucleus accumbens and hippocampus, while MMC, but not METH, self-administration decreased striatal 5-hydroxyindolacetic acid (5-HIAA) concentrations. In summary, MMC supported high levels of self-administration, matching or exceeding those previously reported with other drugs of abuse. Copyright © 2020 by British Association for Psychopharmacologyen_AU
dc.language.isoenen_AU
dc.publisherBritish Association for Psychopharmacologyen_AU
dc.subjectIntravenous injectionen_AU
dc.subjectSerotoninen_AU
dc.subjectDopamineen_AU
dc.subjectAutoradiographyen_AU
dc.subjectBrainen_AU
dc.subjectDrugsen_AU
dc.titleHigh levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamineen_AU
dc.typeJournal Articleen_AU
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.